{Reference Type}: Journal Article
{Title}: Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections.
{Author}: Gavaghan V;Miller JL;Dela-Pena J;
{Journal}: Infection
{Volume}: 51
{Issue}: 2
{Year}: Apr 2023
{Factor}: 7.455
{DOI}: 10.1007/s15010-022-01933-5
{Abstract}: <B>OBJECTIVE: </B>This case series describes real-world utilization of cefiderocol and associated clinical outcomes in the setting of carbapenem-resistant Gram-negative bacterial infections.<BR><B>METHODS: </B>Adult hospitalized patients administered at least 5 days of cefiderocol as definitive treatment from October 1, 2020 to September 16, 2021 were included in this retrospective cohort analysis. The primary outcome was clinical success defined as a composite of 30 day survival, resolution of infection, and absence of 30 day recurrence of the same organism.<BR><B>RESULTS: </B>Among 24 patients, pneumonia (19, 79%) was the most common source of infection with Acinetobacter baumannii (14, 58%) and P. aeruginosa (10, 42%) as the predominant organisms isolated. Cefiderocol monotherapy was used as definitive treatment in 16 (67%) patients. Eleven patients (46%) met clinical success. Thirty-day mortality occurred in ten (42%) patients while seven (29%) patients had recurrence of infection. Thirteen out of 21 total isolates (62%) tested for susceptibility were deemed susceptible. Of the 16 patients with available susceptibility, 9 (56%) had an infection where all isolated organisms were susceptible to cefiderocol.<BR><B>CONCLUSIONS: </B>Our results provide additional insight into the in vivo activity of cefiderocol. Cefiderocol remains a salvage option for carbapenem-resistant Gram-negative organisms.